After an additional 16.4 months of follow-up since the ASCEMBL primary analysis, asciminib showed increasingly superior efficacy compared with bosutinib in patients with CML-CP treated with ≥2 prior TKIs—more patients on asciminib achieved clinically relevant and highly durable responses (BCR::ABL1IS ≤ 1% and MMR) over time [13]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.